• Growth and margin guidance: FY27 revenue growth is projected in the low-to-mid teens driven by volume, while EBITDA margins are expected to be maintained at 27% to 28%.
• Key business drivers: Performance is supported by double-digit growth in Delhi NCR, the SwasthFit portfolio contributing 27% of revenue, the addition of 32 labs and over 2,000 collection centers in the last two years, and recovery in the Suburban business.
• Pricing and realization: Management is not planning any price increases for at least a couple of quarters, expecting 4% to 5% realization growth per patient to continue through test and geographical mix.
• Geographic and regional expansion: Tier 3 and Tier 4 towns now account for roughly 39% of the business without causing margin dilution due to operating leverage, while Mumbai expansion is targeting South Mumbai white spaces through the Shahbazker acquisition.
• FY27 capex outlook: Capital expenditure for FY27 is budgeted between ₹100 crore and ₹120 crore, covering maintenance, new infrastructure expansion, and IT and digital investments.